You have 9 free searches left this month | for more free features.

anti-VEGF

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Macular Edema Due to Type 2 Diabetes Trial in Hangzhou (Anti-VEGF, subthreshold micropulse laser)

Recruiting
  • Macular Edema Due to Type 2 Diabetes Mellitus
  • Anti-VEGF
  • subthreshold micropulse laser
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Feb 26, 2023

Following Intensive Anti-VEGF Therapy in Wet AMD

Completed
  • Age-Related Macular Degeneration
  • Anti-VEGF
  • Budapest, Hungary
  • +1 more
Dec 28, 2022

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept Trial in Tianjin (Vitrectomy combined with ILM peeling, Conbercept

Not yet recruiting
  • Diabetic Macular Edema
  • +2 more
  • Vitrectomy combined with ILM peeling
  • Conbercept intravitreal injection
  • Tianjin, Tianjin, China
    Tianjin medical university eye hosipital
Feb 14, 2023

Macular Degeneration Trial (Zimura, Avastin, Lucentis)

Completed
  • Macular Degeneration
  • (no location specified)
Oct 4, 2022

Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

Active, not recruiting
  • Recurrent Brain Neoplasm
  • Bevacizumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment Trial in Monastir (Bevacizumab Injection

Recruiting
  • Proliferative Diabetic Retinopathy
  • +2 more
  • Bevacizumab Injection [Avastin]
  • Peripheral Retinal Cryoapplication
  • Monastir, Tunisia
    Fattouma Bourguiba University Hospital - Ophthalmology Departmen
Aug 22, 2022

Advanced Cancer Trial in Houston (Dasatinib, Bevacizumab, Paclitaxel)

Completed
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Nov 21, 2022

Proliferative Diabetic Retinopathy Trial in Beijing (proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use)

Recruiting
  • Proliferative Diabetic Retinopathy
  • proactive Anti-VEGF (conbercept) use
  • passive Anti-VEGF (conbercept) use
  • Beijing, Beijing, China
    Peking University Third Hospital
Dec 13, 2022

Neovascular Age-related Macular Degeneration Trial in United States (CLS-AX, Anti-VEGF)

Completed
  • Neovascular Age-related Macular Degeneration
  • Phoenix, Arizona
  • +10 more
Dec 1, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

s in Wet AMD in Active Smokers

Completed
  • Wet Age-related Macular Degeneration
  • Medical Data extraction
  • Brussels, Belgium
    CHU Brugmann
Mar 7, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bevacizumab
  • +4 more
  • Phoenix, Arizona
  • +2 more
Jun 27, 2022

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Adult Diabetic Macular Edema and Suboptimal Response to

Not yet recruiting
  • Diabetic Macular Edema
    • (no location specified)
    Jul 31, 2023

    Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

    Recruiting
    • Resectable Hepatocellular Carcinoma
    • +4 more
    • Atezolizumab
    • +2 more
    • Houston, Texas
    • +1 more
    Oct 12, 2022

    Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • TACE
    • +8 more
    • Quanzhou, Fujian, China
    • +3 more
    Jan 29, 2023

    Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston

    Recruiting
    • Clinical Stage III Cutaneous Melanoma AJCC v8
    • +3 more
    • Boston, Massachusetts
    • +2 more
    Sep 17, 2022

    Exudative Age Related Macular Degeneration Trial in Winston-Salem (Ranibizumab, Photodynamic laser treatment (PDT),

    Not yet recruiting
    • Exudative Age Related Macular Degeneration
    • Winston-Salem, North Carolina
      Wake Forest Health Sciences
    Nov 28, 2022

    Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,

    Not yet recruiting
    • Metastatic Colorectal Carcinoma
    • +3 more
    • Bevacizumab
    • +11 more
    • (no location specified)
    May 9, 2023

    Retinal Telangiectasis, Coats Disease Trial in France (Anti-VEGF injections of bevacizumab, Laser)

    Recruiting
    • Retinal Telangiectasis
    • Coats Disease
    • Anti-VEGF injections of bevacizumab
    • Laser
    • Cergy-Pontoise, France
    • +4 more
    Dec 17, 2021

    Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +2 more
    • Bevacizumab
    • +2 more
    • Los Angeles, California
    • +17 more
    Jan 27, 2023

    Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma Trial in Los Angeles, San Diego (biological, drug, other, genetic)

    Active, not recruiting
    • Giant Cell Glioblastoma
    • +2 more
    • bevacizumab
    • +5 more
    • Los Angeles, California
    • +2 more
    Feb 10, 2022